Determination of 2-Ethylhexanoic Acid Impurity in Clavulanate

Significance of the Topic

The analysis of trace impurities in pharmaceutical intermediates is critical to ensuring drug safety and efficacy. Clavulanic acid, a β-lactamase inhibitor used alongside penicillins and cephalosporins, must meet stringent purity criteria. One key impurity, 2-ethylhexanoic acid, may co-precipitate during secondary purification and requires reliable quantification.

Goals and Overview of the Study

This work aimed to develop a simplified, reagent-free ion chromatography (RFIC™) method for the determination of 2-ethylhexanoic acid in potassium clavulanate. The study replaces conventional solvent extraction and gas chromatography with a direct aqueous injection approach, evaluating method performance against USP monograph requirements.

Methodology and Instrumentation

• System: Dionex ICS-2100 RFIC with isocratic pump, vacuum degasser, eluent generator, high-pressure injector, and column heater.
• Columns: IonPac AG11 guard (2 × 50 mm) and IonPac AS11 analytical (2 × 250 mm).
• Eluent: Electrolytically generated KOH gradient (3 mM for 0–10 min, ramp to 60 mM at 10.1 min, hold to 20.1 min).
• Flow Rate and Temperature: 0.25 mL/min at 30 °C.
• Detection: Suppressed conductivity (ASRS 300, recycle mode; 2 mA during separation, 38 mA during cleanup).

Main Results and Discussion

• Chromatographic separation achieved baseline resolution of 2-ethylhexanoic acid in under 10 minutes, with a 20.1-minute run time including column cleanup.
• Limit of detection (LOD) and quantification (LOQ) were estimated at 0.036 µg/mL (0.0072%) and 0.12 µg/mL (0.024%), respectively, well below the 0.8% acceptance criterion.
• Linearity was confirmed over 1–7 µg/mL (r² = 0.9991), with peak area deviations below 1.5%.
• Accuracy assessed by recovery of spiked samples (0.40%, 0.80%, 1.20%) yielded 94.1 ± 1.7%, 99.0 ± 2.2%, and 100.0 ± 1.0% respectively.
• Precision studies over five days (15 injections/day) showed retention time RSDs up to 0.18% and area RSDs under 2.0%. Daily monitoring of retention time ensured column performance.

Benefits and Practical Applications

• Eliminates solvent extraction and GC-FID steps, reducing sample preparation time and solvent use.
• Uses a lower concentration of API (500 µg/mL vs. 75 mg/mL), conserving material.
• Provides robust, reproducible quantification of 2-ethylhexanoic acid at trace levels.
• Simplifies compliance with USP requirements for impurity analysis.

Future Trends and Potential Applications

Advances in RFIC and suppressor technology may further enhance sensitivity and throughput for trace impurity analysis. Integration with automated sample handling and real-time data processing will support high-volume pharmaceutical quality control. The method may be extended to other organic acid impurities and diverse dosage forms.

Conclusion

The developed RFIC method offers a streamlined, accurate, and sensitive approach for measuring 2-ethylhexanoic acid in potassium clavulanate. It meets USP performance criteria, reduces sample handling, and conserves API. Routine implementation can improve quality control workflows in pharmaceutical manufacturing.

References

1. Reading C, Cole M. Clavulanic Acid: A β-Lactamase-Inhibiting β-Lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother. 1977;11(5):852–857.
2. Cole M et al. Antibiotics. U.S. Patent 4,525,352. June 25, 1985.
3. Saudagar PS, Survase SA, Singhal RS. Clavulanic Acid: A Review. Biotechnol Adv. 2008;26:335–351.
4. Bersanetti PA et al. Kinetic Studies on Clavulanic Acid Degradation. Biochem Eng J. 2005;23:31–36.
5. Hirata DB et al. Precipitation of Clavulanic Acid from Fermentation Broth with Potassium 2-Ethylhexanoate Salt. Sep Purif Technol. 2009;66:598–605.
6. United States Pharmacopeia. Clavulanate Potassium Monograph. USP 33–NF 28; 2010.
7. Dionex Corporation. Using a Reagent-Free Ion Chromatography System to Monitor Trace Anion Contamination in Electronic Component Extracts. App Update 157; 2006.
8. Dionex Corporation. IonPac AG17 and AS17 Columns Product Manual. Doc No. 031529-02; 2002.
9. Dionex Corporation. IonPac AG11 and AS11 Columns Product Manual. Doc No. 034791-12; 2009.
10. United States Pharmacopeia. General Chapter <1225> Validation of Compendial Methods. USP 33–NF 28; 2010.